Base de dados : MEDLINE
Pesquisa : D02.540.600 [Categoria DeCS]
Referências encontradas : 324 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 33 ir para página                         

  1 / 324 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28148783
[Au] Autor:Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
[Ad] Endereço:National Center for Protein Science Shanghai, State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
[Ti] Título:Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
[So] Source:J Virol;91(8), 2017 Apr 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Beta-propiolactone (BPL) is an inactivating agent that is widely used in the vaccine industry. However, its effects on vaccine protein antigens and its mechanisms of action remain poorly understood. Here we present cryo-electron microscopy (cryo-EM) structures of BPL-treated coxsackievirus A16 (CVA16) mature virions and procapsids at resolutions of 3.9 Å and 6.5 Å, respectively. Notably, both particles were found to adopt an expanded conformation resembling the 135S-like uncoating intermediate, with characteristic features including an opened 2-fold channel, the externalization of the N terminus of VP1 capsid protein, and the absence of pocket factor. However, major neutralizing epitopes are very well preserved on these particles. Further biochemical analyses revealed that BPL treatment impairs the abilities of CVA16 particles to bind to the attachment receptor heparan sulfate and to a conformation-dependent monoclonal antibody in a BPL dose-dependent manner, indicating that BPL is able to modify surface-exposed amino acid residues. Taken together, our results demonstrate that BPL treatment may induce alteration of the overall structure and surface properties of a nonenveloped viral capsid, thus revealing a novel mode of action of BPL. Beta-propiolactone (BPL) is commonly used as an inactivating reagent to produce viral vaccines. It is recognized that BPL inactivates viral infectivity through modification of viral nucleic acids. However, its effect on viral proteins remains largely unknown. Here, we present high-resolution cryo-EM structures of BPL-treated coxsackievirus A16 (CVA16) mature virions and procapsids, which reveals an expanded overall conformation and characteristic features that are typical for the 135S-like uncoating intermediate. We further show that the BPL concentration affects the binding of inactivated CVA16 particles to their receptor/antibody. Thus, BPL treatment can alter the overall structure and surface properties of viral capsids, which may lead to antigenic and immunogenic variations. Our findings provide important information for future development of BPL-inactivated vaccines.
[Mh] Termos MeSH primário: Capsídeo/efeitos dos fármacos
Capsídeo/ultraestrutura
Desinfetantes/farmacologia
Enterovirus/efeitos dos fármacos
Enterovirus/ultraestrutura
Propiolactona/farmacologia
Inativação de Vírus
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/imunologia
Anticorpos Antivirais/imunologia
Capsídeo/imunologia
Microscopia Crioeletrônica
Enterovirus/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Viral); 0 (Disinfectants); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170203
[St] Status:MEDLINE


  2 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27523619
[Au] Autor:Kanojia G; Willems GJ; Frijlink HW; Kersten GF; Soema PC; Amorij JP
[Ad] Endereço:Intravacc (Institute for Translational Vaccinology), Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands; University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
[Ti] Título:A Design of Experiment approach to predict product and process parameters for a spray dried influenza vaccine.
[So] Source:Int J Pharm;511(2):1098-111, 2016 Sep 25.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Spray dried vaccine formulations might be an alternative to traditional lyophilized vaccines. Compared to lyophilization, spray drying is a fast and cheap process extensively used for drying biologicals. The current study provides an approach that utilizes Design of Experiments for spray drying process to stabilize whole inactivated influenza virus (WIV) vaccine. The approach included systematically screening and optimizing the spray drying process variables, determining the desired process parameters and predicting product quality parameters. The process parameters inlet air temperature, nozzle gas flow rate and feed flow rate and their effect on WIV vaccine powder characteristics such as particle size, residual moisture content (RMC) and powder yield were investigated. Vaccine powders with a broad range of physical characteristics (RMC 1.2-4.9%, particle size 2.4-8.5µm and powder yield 42-82%) were obtained. WIV showed no significant loss in antigenicity as revealed by hemagglutination test. Furthermore, descriptive models generated by DoE software could be used to determine and select (set) spray drying process parameter. This was used to generate a dried WIV powder with predefined (predicted) characteristics. Moreover, the spray dried vaccine powders retained their antigenic stability even after storage for 3 months at 60°C. The approach used here enabled the generation of a thermostable, antigenic WIV vaccine powder with desired physical characteristics that could be potentially used for pulmonary administration.
[Mh] Termos MeSH primário: Química Farmacêutica/métodos
Vírus da Influenza A
Vacinas contra Influenza/síntese química
Propiolactona/síntese química
[Mh] Termos MeSH secundário: Previsões
Vacinas de Produtos Inativados/síntese química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Influenza Vaccines); 0 (Vaccines, Inactivated); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170424
[Lr] Data última revisão:
170424
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160816
[St] Status:MEDLINE


  3 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27142111
[Au] Autor:Sasaki Y; Yoshino N; Sato S; Muraki Y
[Ad] Endereço:Division of Infectious Diseases and Immunology, Department of Microbiology, School of Medicine, Iwate Medical University, Japan.
[Ti] Título:Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus.
[So] Source:J Virol Methods;235:105-11, 2016 Sep.
[Is] ISSN:1879-0984
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Beta-propiolactone (BPL) is used as an inactivating reagent for influenza virus in a number of countries. However, the treatment of viruses with BPL occasionally results in a decrease in the hemagglutinin (HA) titer, which complicates vaccine development. In the present study, we examined the biological and biochemical characteristics of human H1N1 and H3N2 viruses treated with BPL, and developed an inactivation method for BPL-sensitive viruses. A significant decrease in HA titer was detected in the H3N2 viruses examined. The decrease in the pH of the virus fluid was not associated with the decreased HA titer, indicating that the decrease in HA titer for the H3N2 virus is the result of the direct effect of BPL. Excessive modification of M1 by BPL and loss of virion diameter were observed in 0.1% BPL-treated H3N2 virus. Taken together, these results suggest that the BPL sensitivity of H3N2 virus results from disruption of the virion. By contrast, the H3N2 virus was successfully inactivated by 0.02% BPL without a significant decrease in the HA titer or disruption of virion structure. Furthermore, we found that the 0.02% BPL in the virion preparation was hydrolyzed successfully by incubation at 37°C for 7h. Thus, mild treatment with a low concentration of BPL enabled us to inactivate the H3N2 virus.
[Mh] Termos MeSH primário: Vírus da Influenza A Subtipo H3N2/efeitos dos fármacos
Propiolactona/farmacologia
Inativação de Vírus
[Mh] Termos MeSH secundário: Animais
Cães
Seres Humanos
Hidrólise
Vírus da Influenza A Subtipo H1N1/efeitos dos fármacos
Vírus da Influenza A Subtipo H1N1/ultraestrutura
Vírus da Influenza A Subtipo H3N2/ultraestrutura
Células Madin Darby de Rim Canino
Vírion/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160505
[St] Status:MEDLINE


  4 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26772479
[Au] Autor:Zhang L; Ma J; Fan Y; Zhou Y; Xu J; Liu W; Gu Z; Zeng L
[Ad] Endereço:College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China; Yangtze River Fisheries Research Institute, Chinese Academy of Fishery Sciences, Wuhan 430223, China.
[Ti] Título:Immune response and protection in gibel carp, Carassius gibelio, after vaccination with ß-propiolactone inactivated cyprinid herpesvirus 2.
[So] Source:Fish Shellfish Immunol;49:344-50, 2016 Feb.
[Is] ISSN:1095-9947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Herpesviral haematopoietic necrosis (HVHN) of gibel carp (Carassius gibelio) is a newly emerged infectious disease caused by cyprinid herpesvirus 2 (CyHV-2) and has caused huge economic losses in aquaculture operations. Currently, no effective methods are available for the control of the disease. In this study, ß-propiolactone inactivated cyprinid herpesvirus 2 (CyHV-2) vaccine was prepared, and the immune response and protection in cultured gibel carp after vaccination was thoroughly investigated. This included blood cell counting and classification, phagocytic activity, lysozyme and superoxide dismutase activity, neutralizing antibody titration, immune gene expression analysis, and determination of the relative percent survival in vaccinated gibel carp. The results of blood cell counts indicated that the numbers of the red and white blood cells in the peripheral blood of immunized gibel carp increased significantly at day 4 and day 7 after vaccination (p < 0.01). The differential leukocyte count of neutrophils and monocytes were significantly different compared to the control group at day 4 and 7 and the percentage of lymphocytes reached a peak at day 21. The phagocytic percentage and phagocytic index peaked at day 4 post-vaccination. The lysozyme activity and superoxide dismutase activity were significantly increased compared to the control group (p < 0.01). The serum neutralizing antibody titer peaked (203.03 ± 13.44) at day 21. The qPCR analysis revealed that the expression of the immune genes interlukin 11 and complement component C3 were significantly up-regulated in the immunized group. The challenge test demonstrated that the immunized group had a relative survival rate of 71.4%. These results indicate that the inactivated CyHV-2 vaccine induced both non-specific and specific anti-viral immune responses that resulted in significant protection against HVHN disease and mortality in gibel carp.
[Mh] Termos MeSH primário: Cyprinidae
Infecções por Vírus de DNA/veterinária
Vírus de DNA/imunologia
Doenças dos Peixes/imunologia
Imunidade Humoral
Imunidade Inata
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Infecções por Vírus de DNA/imunologia
Doenças dos Peixes/prevenção & controle
Propiolactona
Vacinas de Produtos Inativados/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Vaccines, Inactivated); 0 (Viral Vaccines); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160117
[St] Status:MEDLINE


  5 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26771141
[Au] Autor:Vujic I; Sanlorenzo M; Esteve-Puig R; Vujic M; Kwong A; Tsumura A; Murphy R; Moy A; Posch C; Monshi B; Rappersberger K; Ortiz-Urda S
[Ad] Endereço:Department of Dermatology, Mt. Zion Cancer Research Center, University of California San Francisco, San Francisco, CA, USA.
[Ti] Título:Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.
[So] Source:Oncotarget;7(6):7297-306, 2016 Feb 09.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Oncogenic NRAS mutations are frequent in melanoma and lead to increased downstream signaling and uncontrolled cell proliferation. Since the direct inhibition of NRAS is not possible yet, modulators of NRAS posttranslational modifications have become an area of interest. Specifically, interfering with NRAS posttranslational palmitoylation/depalmitoylation cycle could disturb proper NRAS localization, and therefore decrease cell proliferation and downstream signaling. Here, we investigate the expression and function of NRAS depalmitoylating acyl protein thioesterases 1 and 2 (APT-1, APT-2) in a panel of NRAS mutant melanoma cells. First, we show that all melanoma cell lines examined express APT-1 and APT-2. Next, we show that siRNA mediated APT-1 and APT-2 knock down and that the specific APT-1 and -2 inhibitors ML348 and ML349 have no biologically significant effects in NRAS mutant melanoma cells. Finally, we test the dual APT-1 and APT-2 inhibitor palmostatin B and conclude that palmostatin B has effects on NRAS downstream signaling and cell viability in NRAS mutant melanoma cells, offering an interesting starting point for future studies.
[Mh] Termos MeSH primário: Inibidores Enzimáticos/farmacologia
GTP Fosfo-Hidrolases/genética
Melanoma/patologia
Proteínas de Membrana/genética
Mutação/genética
Propiolactona/análogos & derivados
Tioléster Hidrolases/metabolismo
[Mh] Termos MeSH secundário: Apoptose/efeitos dos fármacos
Western Blotting
Proliferação Celular/efeitos dos fármacos
Seres Humanos
Melanoma/tratamento farmacológico
Melanoma/enzimologia
Melanoma/genética
Terapia de Alvo Molecular
Propiolactona/farmacologia
RNA Interferente Pequeno/genética
Tioléster Hidrolases/antagonistas & inibidores
Tioléster Hidrolases/genética
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Enzyme Inhibitors); 0 (Membrane Proteins); 0 (RNA, Small Interfering); 0 (palmostatin B); 6RC3ZT4HB0 (Propiolactone); EC 3.1.2.- (LYPLA1 protein, human); EC 3.1.2.- (LYPLA2 protein, human); EC 3.1.2.- (Thiolester Hydrolases); EC 3.6.1.- (GTP Phosphohydrolases); EC 3.6.1.- (NRAS protein, human)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160116
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.6907


  6 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26731189
[Au] Autor:Abd-Elghaffar AA; Ali AE; Boseila AA; Amin MA
[Ad] Endereço:Viral Control Unit, National Organization for Research and Control of Biologicals (NORCB), 51 Wezaret El-Zeraa Street, Agouza, Giza, Egypt. Electronic address: Ph.asmaa.ahmed@gmail.com.
[Ti] Título:Inactivation of rabies virus by hydrogen peroxide.
[So] Source:Vaccine;34(6):798-802, 2016 Feb 03.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Development of safe and protective vaccines against infectious pathogens remains a challenge. Inactivation of rabies virus is a critical step in the production of vaccines and other research reagents. Beta-propiolactone (ßPL); the currently used inactivating agent for rabies virus is expensive and proved to be carcinogenic in animals. This study aimed to investigate the ability of hydrogen peroxide (H2O2) to irreversibly inactivate rabies virus without affecting its antigenicity and immunogenicity in pursuit of finding safe, effective and inexpensive alternative inactivating agents. H2O2 3% rapidly inactivated a Vero cell adapted fixed rabies virus strain designated as FRV/K within 2h of exposure without affecting its antigenicity or immunogenicity. No residual infectious virus was detected and the H2O2-inactivated vaccine proved to be safe and effective when compared with the same virus harvest inactivated with the classical inactivating agent ßPL. Mice immunized with H2O2-inactivated rabies virus produced sufficient level of antibodies and were protected when challenged with lethal CVS virus. These findings reinforce the idea that H2O2 can replace ßPL as inactivating agent for rabies virus to reduce time and cost of inactivation process.
[Mh] Termos MeSH primário: Peróxido de Hidrogênio/química
Vacinas Antirrábicas/imunologia
Vírus da Raiva
Inativação de Vírus
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/sangue
Cercopithecus aethiops
Cobaias
Camundongos
Propiolactona/química
Raiva/prevenção & controle
Vírus da Raiva/imunologia
Vacinas de Produtos Inativados/imunologia
Células Vero
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Rabies Vaccines); 0 (Vaccines, Inactivated); 6RC3ZT4HB0 (Propiolactone); BBX060AN9V (Hydrogen Peroxide)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:160126
[Lr] Data última revisão:
160126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160106
[St] Status:MEDLINE


  7 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26213734
[Au] Autor:Epifano F
[Ti] Título:Dr. Francesco Epifano.
[So] Source:Antiinflamm Antiallergy Agents Med Chem;14(1):1, 2015.
[Is] ISSN:1875-614X
[Cp] País de publicação:United Arab Emirates
[La] Idioma:eng
[Mh] Termos MeSH primário: Terapia Biológica
Biotecnologia/história
Química Farmacêutica/história
Fitoterapia
Policetídeos/uso terapêutico
Propiolactona/uso terapêutico
[Mh] Termos MeSH secundário: Bactérias
Fungos
História do Século XX
História do Século XXI
Seres Humanos
Itália
Masculino
Plantas
Policetídeos/química
Propiolactona/análogos & derivados
Propiolactona/química
[Pt] Tipo de publicação:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE; PORTRAITS
[Ps] Nome de pessoa como assunto:epifano F
[Nm] Nome de substância:
0 (Polyketides); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:150724
[Lr] Data última revisão:
150724
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150728
[St] Status:MEDLINE


  8 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25997377
[Au] Autor:Pawar SD; Murtadak VB; Kale SD; Shinde PV; Parkhi SS
[Ad] Endereço:National Institute of Virology-Microbial Containment Complex, 130/1, Sus Road, Pashan, Pune 411021, India. Electronic address: pawarshailesh@hotmail.com.
[Ti] Título:Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.
[So] Source:J Virol Methods;222:28-33, 2015 Sep 15.
[Is] ISSN:1879-0984
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:In view of the emerging avian influenza (AI) viruses, it is important to study the susceptibility of AI viruses to inactivating agents for preparation of antigens and inactivated vaccines. The available information on susceptibility of both the high and low pathogenic AI viruses to different inactivating agents is inadequate and ambiguous. It has been shown that different subtypes of influenza viruses require different physical and chemical conditions for inactivation of infectivity. The present study was undertaken to evaluate the use of beta-propiolactone (BPL), formalin and ether for inactivation and its impact on antigenicity of AI viruses. A total of nine high and low pathogenic AI viruses belonging to four influenza A subtypes were included in the study. The H5N1 viruses were from the clades 2.2, 2.3.2.1 and 2.3.4. The H9N2 virus included in the study was of the G1 genotype, while the H11N1 and H4N6 viruses were from the Eurasian lineage. The viruses were treated with BPL, formalin and with ether. The confirmation of virus inactivation was performed by two serial passages of inactivated viruses in embryonated chicken eggs. The infectivity of all tested AI viruses was eliminated using 0.1% BPL and 0.1% formalin. Ether eliminated infectivity of all tested low pathogenic AI viruses; however, ether with 0.2% or 0.5% Tween-20 was required for inactivation of the highly pathogenic AI H5N1 viruses. Treatment with BPL, ether and formalin retained virus hemagglutination (HA) titers. Interestingly ether treatment resulted in significant rise in HA titers (P<0.05) of all tested AI viruses. This data demonstrated the utility of BPL, formalin and ether for the inactivation of infectivity of AI viruses used in the study for the preparation of inactivated virus antigens for research and diagnosis of AI.
[Mh] Termos MeSH primário: Desinfetantes/farmacologia
Desinfecção/métodos
Vírus da Influenza A/efeitos dos fármacos
Vírus da Influenza A/fisiologia
Influenza Aviária/virologia
Viabilidade Microbiana/efeitos dos fármacos
Inativação de Vírus
[Mh] Termos MeSH secundário: Animais
Antígenos/isolamento & purificação
Embrião de Galinha
Galinhas
Éter/farmacologia
Formaldeído/farmacologia
Testes de Inibição da Hemaglutinação
Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia
Vírus da Influenza A/crescimento & desenvolvimento
Vírus da Influenza A/isolamento & purificação
Propiolactona/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antigens); 0 (Disinfectants); 0 (Hemagglutinin Glycoproteins, Influenza Virus); 0F5N573A2Y (Ether); 1HG84L3525 (Formaldehyde); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:150807
[Lr] Data última revisão:
150807
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150523
[St] Status:MEDLINE


  9 / 324 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25862300
[Au] Autor:Pereira RC; Silva AN; Souza MC; Silva MV; Neves PP; Silva AA; Matos DD; Herrera MA; Yamamura AM; Freire MS; Gaspar LP; Caride E
[Ad] Endereço:Oswaldo Cruz Foundation (FIOCRUZ), Bio-Manguinhos, Avenida Brasil 4365, 21045-900, Rio de Janeiro, RJ, Brazil.
[Ti] Título:An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures.
[So] Source:Vaccine;33(35):4261-8, 2015 Aug 20.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Yellow fever is an acute infectious disease caused by prototype virus of the genus Flavivirus. It is endemic in Africa and South America where it represents a serious public health problem causing epidemics of hemorrhagic fever with mortality rates ranging from 20% to 50%. There is no available antiviral therapy and vaccination is the primary method of disease control. Although the attenuated vaccines for yellow fever show safety and efficacy it became necessary to develop a new yellow fever vaccine due to the occurrence of rare serious adverse events, which include visceral and neurotropic diseases. The new inactivated vaccine should be safer and effective as the existing attenuated one. In the present study, the immunogenicity of an inactivated 17DD vaccine in C57BL/6 mice was evaluated. The yellow fever virus was produced by cultivation of Vero cells in bioreactors, inactivated with ß-propiolactone, and adsorbed to aluminum hydroxide (alum). Mice were inoculated with inactivated 17DD vaccine containing alum adjuvant and followed by intracerebral challenge with 17DD virus. The results showed that animals receiving 3 doses of the inactivated vaccine (2 µg/dose) with alum adjuvant had neutralizing antibody titers above the cut-off of PRNT50 (Plaque Reduction Neutralization Test). In addition, animals immunized with inactivated vaccine showed survival rate of 100% after the challenge as well as animals immunized with commercial attenuated 17DD vaccine.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Vacina contra Febre Amarela/imunologia
Febre Amarela/prevenção & controle
Vírus da Febre Amarela/crescimento & desenvolvimento
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/biossíntese
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/biossíntese
Anticorpos Antivirais/imunologia
Reatores Biológicos/virologia
Cercopithecus aethiops
Desinfetantes/farmacologia
Imunidade Humoral
Esquemas de Imunização
Camundongos Endogâmicos C57BL
Testes de Neutralização
Propiolactona/farmacologia
Análise de Sobrevida
Vacinas de Produtos Inativados/administração & dosagem
Vacinas de Produtos Inativados/imunologia
Células Vero
Cultura de Vírus
Vacina contra Febre Amarela/administração & dosagem
Vírus da Febre Amarela/imunologia
Vírus da Febre Amarela/isolamento & purificação
Vírus da Febre Amarela/patogenicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Disinfectants); 0 (Vaccines, Inactivated); 0 (Yellow Fever Vaccine); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150822
[Lr] Data última revisão:
150822
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150412
[St] Status:MEDLINE


  10 / 324 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25413278
[Au] Autor:Pérez C; Neill JL; Muckle MT; Zaleski DP; Peña I; Lopez JC; Alonso JL; Pate BH
[Ad] Endereço:Department of Chemistry, University of Virginia, McCormick Road, Charlottesville, VA 22903 (USA).
[Ti] Título:Water-water and water-solute interactions in microsolvated organic complexes.
[So] Source:Angew Chem Int Ed Engl;54(3):979-82, 2015 Jan 12.
[Is] ISSN:1521-3773
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:A structural study of microsolvated clusters of ß-propiolactone (BPL) formed in a pulsed molecular jet expansion is presented. The rotational spectra of BPL-(H2O)n (n=1-5) adducts have been analyzed by broadband microwave spectroscopy. Unambiguous identification of the structures has been achieved using isotopic substitution and experimental measurements of the cluster dipole moment. The observed structures are discussed in terms of the different intermolecular interactions between water molecules and between water and BPL, which include n-π* interactions involving the lone pairs of electrons on water oxygen atoms and the antibonding orbital of the BPL carbonyl group. The changes induced in the structures of the water hydrogen-bonding network by complexation to BPL indicate that water clusters adopt specific configurations to maximize their links to solute molecules.
[Mh] Termos MeSH primário: Propiolactona/química
Soluções/química
Água/química
[Mh] Termos MeSH secundário: Ligações de Hidrogênio
Isomerismo
Marcação por Isótopo
Espectrofotometria Infravermelho
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Solutions); 059QF0KO0R (Water); 6RC3ZT4HB0 (Propiolactone)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:150113
[Lr] Data última revisão:
150113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141122
[St] Status:MEDLINE
[do] DOI:10.1002/anie.201409057



página 1 de 33 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde